Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients. GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder and related lower urinary tract symptoms. - Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: decreases the frequency of sudden urges to void. - Urinary frequency: lowers the number of daytime voids. - Urge urinary incontinence: lessens episodes of involuntary leakage.

Adverse reactions have been reported with mirabegron use.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: persistent or intermittent head pain. - Dry mouth: reduced salivation. - Constipation: decreased bowel movements. - Urinary retention: difficulty initiating or completing urination.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat. - Severe hypertension: markedly high blood pressure requiring medical intervention. - Acute urinary retention requiring catheterisation. - Allergic reactions: rash, pruritus, or anaphylaxis. - Myocardial infarction: rare cardiac events.

Mirabegron should be used with attention to several safety considerations. - Blood pressure monitoring: check baseline and periodic readings. - Renal function assessment: evaluate creatinine clearance before initiation. - Urinary retention risk: assess for pre‑existing obstruction. - Uncontrolled hypertension: avoid use in patients with severe hypertension. - Concomitant anticholinergics: monitor for additive urinary retention. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mirabegron may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase mirabegron exposure. - Strong CYP2D6 inhibitors (e.g., paroxetine): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP2D6 substrate drugs (e.g., metoprolol): reduced efficacy may occur. - Antihypertensive agents: possible attenuation of blood‑pressure‑lowering effect. - Diuretics: may enhance risk of hypertension. - NSAIDs: can contribute to blood‑pressure elevation.